Intra-Cellular Therapies (ITCI) Expected to Announce Earnings on Thursday

Intra-Cellular Therapies (NASDAQ:ITCI) is expected to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $193.29 million for the quarter.

Intra-Cellular Therapies Trading Up 0.5 %

Shares of NASDAQ ITCI opened at $128.60 on Thursday. The firm’s 50-day moving average price is $108.45 and its 200-day moving average price is $89.01. Intra-Cellular Therapies has a 1-year low of $62.78 and a 1-year high of $128.75. The firm has a market capitalization of $13.67 billion, a P/E ratio of -147.81 and a beta of 0.72.

Analyst Upgrades and Downgrades

ITCI has been the topic of several research reports. Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Baird R W lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Leerink Partnrs lowered shares of Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Needham & Company LLC reiterated a “hold” rating and set a $100.00 price objective on shares of Intra-Cellular Therapies in a report on Monday, January 13th. Finally, StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a report on Sunday. They set a “hold” rating on the stock. Nine equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $103.62.

Insider Buying and Selling at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 51,000 shares of the stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $85.80, for a total value of $4,375,800.00. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares in the company, valued at approximately $91,834,228.20. This trade represents a 4.55 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 2.60% of the company’s stock.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.